GTCR, a leading private equity firm, announces that it has signed and completed the sale of Antylia Scientific (“Antylia” or “the Company”) to Brookfield Asset Management’s private equity business and CDPQ for approximately $1.34 billion. Headquartered in Vernon Hills, Illinois, Antylia is a diversified life sciences company focused on the biopharmaceutical, clinical diagnostic, and environmental testing industries, among others. Antylia supports the accuracy and repeatability of processes in research and clinical labs by manufacturing and selling mission-critical products to thousands of long-term customers across these industries. Since 2014, Antylia has completed 15 add-on acquisitions of complementary life science tools and diagnostic controls businesses.
Read the full article: GTCR Announces Sale of Antylia Scientific //
Source: https://www.prnewswire.com/news-releases/gtcr-announces-sale-of-antylia-scientific-302467006.html